Climb Bio, Inc.
NASDAQ:CLYM · NASDAQ Global Market
+$0.02 today
Vol 1.06M · Avg 0.88M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-37.3%
avg -42.3%
ROIC
-42.2%
avg -43.9%
ROA
-35.7%
avg -39.6%
Analysis
ROA is currently the strongest return metric at -35.7% versus its period average of -39.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Aoife Brennan BCh MMSc | Chief Executive Officer, President & Director | $1.09M | — | 50 | $700,000.00 | 1.03% |
Perrin Wilson | Chief Business Officer | $793,420.00 | — | 47 | $300,000.00 | 0.44% |
Susan Altschuller | CFO & Principal Accounting Officer | $570,812.00 | — | 44 | $142,500.00 | 0.21% |
Edgar D. Charles | Chief Medical Officer | — | — | — | — | — |
Ashley Jones | Senior Vice President of People & Workforce Strategy | — | — | — | — | — |
Theresa Donegan | Vice President & Head of Quality | — | — | — | — | — |
Janaki Subramanyam | Vice President & Head of Regulatory Affairs | — | — | — | — | — |
Adam Villa | Senior Vice President of Technical Operations | — | — | — | — | — |
Chandra Adams | VP, General Counsel & Secretary | — | — | — | — | — |
Cindy J. Driscoll | Senior VP of Finance & Principal Accounting Officer | — | — | 60 | $100,000.00 | 0.15% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$779,625.64
Sells
5
$904,535.80
Net Sentiment
$124,910.16
Net selling
Most Active
Thomas Stephen Basil
4 transactions
Analysis
Insiders reported 3 buys worth $779,625.64 and 5 sells worth $904,535.80 over the last 12 months. That adds up to net selling of $124,910.16. Thomas Stephen Basil was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Turn Therapeutics Inc.
NASDAQ:TTRX
$178.13M
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
$137.37M
Spero Therapeutics, Inc.
NASDAQ:SPRO
$130.57M
Agenus Inc.
NASDAQ:AGEN
$122.65M
Anixa Biosciences, Inc.
NASDAQ:ANIX
$88.63M
Entera Bio Ltd.
NASDAQ:ENTX
$59.64M
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
$58.95M
Seres Therapeutics, Inc.
NASDAQ:MCRB
$58.83M
Actuate Therapeutics Inc
NASDAQ:ACTU
$50.36M
VistaGen Therapeutics, Inc.
VTGN
$22.30M
Who manages CLYM?
Climb Bio, Inc. (CLYM) lists 10 active executives. The top listed executive is Aoife Brennan BCh MMSc, Chief Executive Officer, President & Director.
Are CLYM insiders buying or selling?
Recent insider activity shows net buying of $13.11M.
Explore More
Continue the stock analysis
Jump to another research area for this company.